Multiple Kinase Small Molecule Inhibitor Tinengotinib ( TT ‐00420) Alone or With Chemotherapy Inhibit the Growth of SCLC
Cancer Science · 2025
DOI: 10.1111/cas.16450 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Hui Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Biobank, Jilin Cancer Hospital, Changchun, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Protein Kinase Inhibitors, Pyrimidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Scientific Research Funds of Jilin Province of Health and Family Planning Commission, Department of Science and Technology of Jilin Province, National Cancer Center.
Themen: Onkologische Pflege
Abstract (Originalsprache)
There is an urgent need to develop new targeted treatment agents for small cell lung cancer (SCLC). Tinengotinib (TT‐00420) is a novel, multi‐targeted, and spectrally selective small‐molecule kinase inhibitor that has shown significant inhibitory effects on certain solid tumors in preclinical studies. However, its role and mechanism of action in SCLC remain unclear. In this study, we demonstrated that tinengotinib effectively inhibited SCLC cell proliferation, especially highly expressing NeuroD1 (SCLC‐N), in the SCLC cell line‐derived xenograft (CDX) model and the malignant pleural effusion cell model of patients with SCLC. When combined with etoposide/cisplatin, it synergistically inhibited SCLC growth. Tinengotinib regulates proliferation, apoptosis, migration, cell cycle and angiogenesis in SCLC cells. Mechanistic studies revealed that c‐Myc expression may be a key factor influencing the effect of tinengotinib in SCLC‐N. This study provides reliable preclinical data and a new direction for tinengotinib as a promising therapy for SCLC, either alone or in combination with chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biobank, Jilin Cancer Hospital, Changchun, China.
- Medical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun, China.
- Postdoctoral Research Workstation, Jilin Cancer Hospital, Changchun, China.
- Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China.
- TransThera Sciences (Nanjing). Inc. Fl 3, Bld 9, Phase 2 Accelerator, Biotech and Pharmaceutical Valley, Jiangbei New Area, Nanjing, Jiangsu, China.
ORCID-Profile: Chenchen Tang, Yuanhua Lu
Förderung
- Scientific Research Funds of Jilin Province of Health and Family Planning Commission
- Department of Science and Technology of Jilin Province
- National Cancer Center
Zitieren
APA
Li, H., Tang, C., Zhao, P., Zhong, R., Lu, Y., Liu, Y., Li, R., Lan, S., Wu, C., Qiang, X., Peng, P., Wu, F., Cheng, Y., & Liu, Y. (2025). Multiple Kinase Small Molecule Inhibitor Tinengotinib ( TT ‐00420) Alone or With Chemotherapy Inhibit the Growth of SCLC. Cancer Science. https://doi.org/10.1111/cas.16450
Vancouver
Li H, Tang C, Zhao P, Zhong R, Lu Y, Liu Y, et al. Multiple Kinase Small Molecule Inhibitor Tinengotinib ( TT ‐00420) Alone or With Chemotherapy Inhibit the Growth of SCLC. Cancer Science. 2025. doi:10.1111/cas.16450
BibTeX
@article{Li2025,
author = {Li, Hui and Tang, Chenchen and Zhao, Peiyan and Zhong, Rui and Lu, Yuanhua and Liu, Yan and Li, Rixin and Lan, Shaowei and Wu, Chunjiao and Qiang, Xiaoyan and Peng, Peng and Wu, Frank and Cheng, Ying and Liu, Ying},
title = {Multiple Kinase Small Molecule Inhibitor Tinengotinib ( TT ‐00420) Alone or With Chemotherapy Inhibit the Growth of SCLC},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.16450}
}
EUVIMED